Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Masimo Corporation - Common Stock (NQ: MASI )

166.09 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Jan 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Masimo Corporation - Common Stock

< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
European Society of Anaesthesiology and Intensive Care (ESAIC) Recommends Noninvasive, Continuous Hemoglobin Monitoring
From Masimo
Via Business Wire
New Study Finds That Masimo PVi® Reliably Predicted Fluid Responsiveness in Young Children Undergoing Neurosurgery
From Masimo
Via Business Wire
Masimo and Temple Health Form Innovation Collaboration with Focus on Hospital Automation and Telehealth Initiatives
From Masimo
Via Business Wire
Expert Ratings for Masimo
Via Benzinga
New Study Evaluates the Use of Masimo PVi® As an Indicator of Fluid Responsiveness to Guide Goal-Directed Fluid Therapy in Adult Neurosurgical Patients
From Masimo
Via Business Wire
$300B California Teachers Pension Fund Joins Politan Capital In Legal Action Against Masimo CEO's Employment Agreement
Via Benzinga
CalSTRS Joins Politan Capital Management in Legal Action Against Masimo CEO’s Employment Agreement
From Politan Capital Management
Via Business Wire
Masimo to Present in 44th Annual Raymond James Institutional Investors Conference
From Masimo
Via Business Wire
The Latest Analyst Ratings for Masimo
Via Benzinga
Masimo Reports Fourth Quarter and Full-Year 2022 Financial Results
From Masimo
Via Business Wire
Analyst Says This MedTech Giant Stock Offers 'Too Much Optionality,' Upgrades Rating
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 22, 2023
Via Benzinga
New Study Evaluates the Utility of Masimo ORi™ in Reducing Hyperoxemia During Laparoscopic Gastrectomy
From Masimo
Via Business Wire
Masimo Centroid® Receives Innovative Technology Designation from Vizient
From Masimo
Via Business Wire
Masimo to Report Fourth Quarter and FY 2022 Financial Results After Market Close on Tuesday, February 28
From Masimo
Via Business Wire
Thoughts For Thursday: Risk-off, Risk-on
The one foot forward, one foot backward action continues on Wall Street, though yesterday it was more like three or four steps backward. It seems Q1 earnings jitters are responsible. 
Via Talk Markets
NeurAxis: Should You Buy This IPO?
As NeurAxis is ready to launch its IPO, we take a closer look to see if investors should be buying into the hype. 
Via Talk Markets
Masimo Announces the Limited Market Release of Visual Clinical Activity Monitoring (VCAM™)
From Masimo
Via Business Wire
Intuitive Surgical Stock Hits 80-Plus Relative Strength Rating Benchmark
On Monday, Intuitive Surgical stock had its Relative Strength (RS) Rating upgraded to 81, up from 73 a day earlier. 
Via Investor's Business Daily
InMode Stock Glowing Again As Cosmetic Surgery Market Recovers
The upwardly revised 75 RS Rating shows InMode stock outperformed 75% of all stocks over the past year. Its other ratings are even better. 
Via Investor's Business Daily
Researchers Harness the Power of Masimo Root®’s Advanced Multimodal Monitoring Capabilities to Study the Impact of Different Ventilatory Strategies on Brain Oxygenation During Thoracoscopic Surgery
From Masimo
Via Business Wire
Masimo and Philips Expand Partnership to Improve Telehealth for Patients and Clinicians Around the World with the Masimo W1™ Watch
From Masimo
Via Business Wire
How Masimo Is Taking On Electronics Giant Apple — And Winning
Apple could be on the hook for a royalty tied to its Apple Watch. 
Via Investor's Business Daily
Apple Watch Faces Potential Import Ban As US Judge Rules Against Tech Giant In Patent Infringement Case
Via Benzinga
ITC Judge Rules Apple Violated U.S. Trade Laws by Infringing Masimo Pulse Oximeter Patent
From Masimo
Via Business Wire
New Study Evaluates the Performance of Masimo SpHb® Noninvasive Spot-Check Hemoglobin in the Emergency Department
From Masimo
Via Business Wire
New Study Finds That Masimo Patient SafetyNet™ Helped Clinicians Reduce CPR Events and Rates, Improve CPR Success Rate, and Reduce Hospital Length of Stay and Mortality
From Masimo
Via Business Wire
Masimo to Present in 41st Annual J.P. Morgan Healthcare Conference
From Masimo
Via Business Wire
New Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean Section
From Masimo
Via Business Wire
$7.5 Million Bet On This Financial Services Stock? Check Out These 3 Stocks Insiders Are Buying
Although US stocks closed lower on Monday, there were a few notable insider trades. 
Via Benzinga
< Previous 1 2
...
12 13 14 15 16 17 18 19 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.